We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VRTX icon
1
CALL
Vertex Pharmaceuticals
VRTX
$132B
$255M 9.78%
22,669
-7,167
-24% -$682K
GILD icon
2
PUT
Gilead Sciences
GILD
$182B
$147M 5.64%
13,803
+4,147
+43% +$406K
BIIB icon
3
CALL
Biogen
BIIB
$32.1B
$138M 5.31%
4,180
+692
+20% +$228K
VRTX icon
4
PUT
Vertex Pharmaceuticals
VRTX
$132B
$108M 4.14%
9,592
-374
-4% -$35.6K
SPY icon
5
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
$86.4M 3.32%
+4,386
New +$867K
ACHC icon
6
CALL
Acadia Healthcare
ACHC
$2.61B
$69.5M 2.67%
+28,073
New +$1.37M
OEF icon
7
PUT
iShares S&P 100 ETF
OEF
$20.2B
$57.8M 2.22%
5,289
+1,123
+27% +$98.9K
AGN
8
PUT
DELISTED
Allergan plc
AGN
$48.4M 1.86%
2,008
+1,258
+168% +$282K
BMY icon
9
CALL
Bristol-Myers Squibb
BMY
$131B
$46.7M 1.79%
9,134
+7,721
+546% +$386K
ABBV icon
10
CALL
AbbVie
ABBV
$463B
$43.9M 1.69%
7,607
-5,294
-41% -$294K
AZN icon
11
PUT
AstraZeneca
AZN
$254B
$40.4M 1.55%
4,639
+3,647
+368% +$267K
MRK icon
12
CALL
Merck
MRK
$357B
$37.5M 1.44%
+6,623
New +$372K
AGN
13
CALL
DELISTED
Allergan plc
AGN
$37M 1.42%
1,533
+758
+98% +$170K
A icon
14
CALL
Agilent Technologies
A
$41.4B
$28.7M 1.1%
+7,033
New +$287K
LLY icon
15
CALL
Eli Lilly
LLY
$1.01T
$28.3M 1.09%
+4,359
New +$276K
TSLA icon
16
PUT
Tesla
TSLA
$1.42T
$28.2M 1.08%
17,415
+2,490
+17% +$41.1K
CELG
17
PUT
DELISTED
Celgene Corp
CELG
$26M 1%
2,748
-378
-12% -$34.1K
GILD icon
18
CALL
Gilead Sciences
GILD
$182B
$24.4M 0.94%
2,288
-718
-24% -$70.3K
IOC
19
PUT
DELISTED
Interoil Corporation
IOC
$23.6M 0.91%
4,350
+983
+29% +$57.3K
CELG
20
CALL
DELISTED
Celgene Corp
CELG
$22M 0.84%
2,320
-948
-29% -$85.6K
MNKD icon
21
CALL
MannKind Corp
MNKD
$1.21B
$19.8M 0.76%
6,688
+2,085
+45% +$82.3K
OPK icon
22
CALL
Opko Health
OPK
$1.16B
$19M 0.73%
22,323
-338
-1% -$2.97K
AZN icon
23
CALL
AstraZeneca
AZN
$254B
$18.9M 0.72%
1,503
+351
+30% +$25.7K
ALNY icon
24
CALL
Alnylam Pharmaceuticals
ALNY
$33.5B
$18.4M 0.71%
2,355
+2,260
+2,379% +$146K
MDVN
25
CALL
DELISTED
MEDIVATION, INC.
MDVN
$17.7M 0.68%
+3,576
New +$152K

Similar funds

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.